China Pharma Holdings, INC

China Pharma Holdings Inc. announced the pricing of a registered direct offering, raising $5 million in gross proceeds to fund working capital and general corporate purposes.

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for Prinsepia Utilis Esterol Sublingual Tablets for $6.93 million, paid in common stock.

China Pharma Holdings' subsidiary, Helpson, has acquired an invention patent for a Topiroxostat Nanoemulsion for $8.82 million, paid in company stock.

China Pharma Holdings' stockholders approved a reverse stock split, elected three independent directors, and adopted an amendment to its long-term incentive plan at its annual meeting.

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for Ipragliflozin tablets for $9.8 million, paid in common stock.

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for a Captopril microcapsule and its preparation method for $6.3 million, paid in 3.5 million restricted common shares.

China Pharma Holdings reports continued net losses and declining revenue, raising substantial doubt about its ability to continue as a going concern.

China Pharma Holdings, Inc. reported a reduced net loss for the first half of 2025, but continues to face substantial doubt about its ability to continue as a going concern.

China Pharma Holdings saw a decrease in revenue for the first quarter of 2025, primarily due to increased competition from generic drugs in China.

China Pharma Holdings experienced a decrease in revenue during the third quarter of 2024, primarily due to increased competition and the impact of centralized procurement policies in China.

China Pharma Holdings reported a decrease in revenue and a net loss for the second quarter of 2024, primarily due to increased competition and the impact of centralized procurement policies in China.

China Pharma Holdings experienced a 30.1% decrease in revenue and an increased net loss in the first quarter of 2024 compared to the same period in 2023.

China Pharma Holdings reports a decline in revenue for fiscal year 2024 due to increased competition and regulatory changes in the Chinese pharmaceutical market.

China Pharma Holdings acquired new drug patents for chronic obstructive pulmonary disease and psoriasis while facing revenue declines and a net loss in 2023.

China Pharma Holdings, Inc. will hold its Annual Meeting to vote on a reverse stock split, an independent director election, and an amendment to its long-term incentive plan.

China Pharma Holdings is asking stockholders to vote on key proposals at its upcoming annual meeting, including a reverse stock split to maintain NYSE American listing and an amendment to its long-term incentive plan.